Skip to main content

Month: August 2021

Rovio Entertainment Corp.: Rovio Entertainment to acquire hyper-casual game studio Ruby Games

Rovio Entertainment Corporation              Stock Exchange Release              August 12, 2021, at 8.45 a.m. EEST Rovio Entertainment to acquire hyper-casual game studio Ruby Games Entry into hyper-casual market diversifies and grows Rovio’s audience and market footprint The acquisition will bring a new profitable growth vector for Rovio. Espoo, Finland, August 12, 2021 – Rovio Entertainment Corporation, the creator of Angry Birds, has entered into an agreement to acquire 100% of the shares in Ruby Games, a hyper-casual studio based in Izmir, Turkey. Ruby Games is the creator of the hit game, Hunter Assassin, the sixth most downloaded game in the world in 2020. Under the terms of agreement, Rovio will acquire Ruby Games in multiple tranches. In the first tranche Rovio will acquire 20% of Ruby’s shares for USD 10 million in cash....

Continue reading

Ultimovacs Announces Further Positive Topline Results from Phase I UV1 Cancer Vaccine Combination Study in Metastatic Melanoma

Cohort 2 showed 60% objective response rate, 30% complete response rate 90% overall survival rate at 12 months follow-up Cohort 2 results reinforce results seen in cohort 1 Good safety and tolerability profile supports use of UV1 in combination treatmentsOslo, 12 August 2021: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced positive topline results from the second cohort of 10 patients after one year of its ongoing U.S.-based Phase I clinical trial evaluating the Company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. The primary endpoint of safety and tolerability was achieved with strong initial signs of clinical response. Tumor shrinkage was...

Continue reading

NNIT A/S: 08/2021 Financial report for the first six months of 2021

Company announcement 08/2021: Financial report for the first six months of 2021 Revenue increase of 1.3% and an operating profit margin before special items of 5.1% Performance highlights for the second quarter of 2021New CEO Pär Fors took office as CEO of NNIT on June 14, 2021 Revenue increased to DKK 710m, up 1.3% (-1.8% organic) from Q2 2020, driven by:Life Sciences (excluding Novo Nordisk Group) grew to DKK 234m, up 35% (22% organic). The increase was related to the continued significant growth of the Life Sciences International business, where revenues increased by 56% (36% organic) to DKK 165m, while revenue from Life Sciences Denmark increased by 1.5% to DKK 69m. Novo Nordisk Group revenue declined 13.7% to DKK 151m. On June 29, 2021 NNIT secured the extension of the Novo Nordisk Group global IT infrastructure contract for five...

Continue reading

Hexagon Composites ASA: Second quarter and half year results 2021

Hexagon had an active quarter with strong demand and multiple important ​contract awards. Capacity expansion plans underway based on positive outlook. Highlights in Q2 2021Hexagon Agility received orders from major global logistics customer with an estimated total value of USD 23.7 million (approx. NOK 211 million). Hexagon Agility received an order from Estes Express Lines for compressed natural gas (CNG)/renewable natural gas (RNG) fuel systems with a value of USD 8 million (approx. NOK 71 million) Empresa Municipal de Transporte (EMT) in Madrid announced a tender award of 520 compressed renewable natural gas (RNG) buses. Solaris, Mercedes Benz and Scania, all customers of Hexagon Agility, will supply the buses to EMT Hexagon Agility received order from REV LNG for Mobile Pipeline® modules to deliver Renewable Natural Gas with an estimated...

Continue reading

Hexatronic Group – Interim report January – June 2021

Hexatronic Group AB (publ)Interim report January – June 2021 Events during the quarterHexatronic signed three agreements in Germany to a total value of MSEK 70. Hexatronic establish 5G training through the acquisition of Mpirical Ltd. in UK. Hexatronic has issued a redundancy notice for the fiber optics assembly operation in Örebro, with the aim of relocating all production to Baltronic in Estonia and coordinating our warehouses in Sweden to Hudiksvall. The relocation is part of efforts to strengthen the company’s competitiveness on a growing international market, while the Swedish market is expected to decrease in the coming years.Events since the end of the periodHexatronic has signed a binding asset purchase agreement to acquire all the telecom activities of REHAU Group – one of the main players in the German microduct market. Hexatronic...

Continue reading

Mowi ASA (OSE:MOWI): Presentation of Q2 2021 results 25 August 2021 at 08:00 (CET)

Mowi ASA hereby invites you to the presentation of the results for the second quarter 2021. The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/ A recording of the webcast will be made available on our website immediately afterwards. Please note that the quarterly report and presentation will be published at 06:30 (CET).This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue reading

Lerøy Seafood Group ASA: Invitation to presentation of results for Q2 and first half 2021

Lerøy Seafood Group ASA will publish its results for Q2 and first half on 19 August 2021. The quarterly report and presentation will be published at 06:30 CET. The results will be presented in Norwegian through a live webcast followed by a Q&A session at 08:00 CET on www.leroyseafood.com. A presentation in English through webcast will be available from 12:00 CET on www.leroyseafood.com. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.  

Continue reading

Calcium Carbonate Market worth USD 63.87 Billion by 2028, registering a CAGR of 5.87% – Report by Market Research Future (MRFR)

New York, Aug. 12, 2021 (GLOBE NEWSWIRE) — Calcium Carbonate Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Calcium Carbonate Market: Information by End-use Industry, by Product Type, and Region – Forecast till 2028.”, The market is projected to be worth USD 63.87 Billion by 2028, registering a CAGR of 5.87% during the forecast period (2021 – 2028), The market was valued at USD USD 41.4 billion in 2020. Market Scope: Calcium carbonate is extensively used as a stomach antacid and in the production of lime and Portland cement. The market is primarily driven by rising calcium carbonate use in various end-use sectors, such as paper, paints and coatings, and plastics. Carbonate is abundant in geologic environments and serves as a massive carbon storehouse. The calcium cycle...

Continue reading

Fiber Cement Market worth USD 24.87 Billion by 2028, registering a CAGR of 5.59% – Report by Market Research Future (MRFR)

New York, Aug. 12, 2021 (GLOBE NEWSWIRE) — Fiber Cement Market Overview: According to a comprehensive research report by Market Research Future (MRFR), “Fiber Cement Market: Information by Product, Application, End Use, and Region – Forecast till 2028.”, The market is projected to be worth USD 24.87 Billion by 2028, registering a CAGR of 5.59% during the forecast period (2021 – 2028), The market was valued at USD USD 16.4 billion in 2020. List of the Key Companies Profiled in the Fiber Cement Market Research Report are:James Hardie Industries PLC (Ireland) Allura (US) Cembrit Holding A/S (Denmark) CSR Limited (Australia) Etex Group NV (Belgium) Toray Industries Inc. (US) American Fiber Cement Corporation (US) Nichiha (Japan) GAF (US) Shandong Lutai Building Material Science and Technology Group Co., Ltd (China)Get...

Continue reading

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum. All of the shares in the offering are being sold by Fulcrum. In addition, Fulcrum has granted the underwriters a 30-day option to purchase up to 990,000 additional shares of its common stock at the public offering price, less the underwriting discount and commissions. The offering is expected to close on August...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.